Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis

Company Overview

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.98 to $1.49
• 52-Week Range: N/A
• Volume: 296,500 shs
• Average Volume: 396,682 shs
• Market Capitalization: $69.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OSMT Stock Analysis - Frequently Asked Questions

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.06. The business earned $2.20 million during the quarter, compared to analyst estimates of $2.39 million. Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative trailing twelve-month return on equity of 81.23%.

When did Osmotica Pharmaceuticals IPO?

Osmotica Pharmaceuticals (OSMT) raised $58 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO.

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Osmotica Pharmaceuticals investors own include Canopy Growth (CGC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), NIO (NIO), Allena Pharmaceuticals (ALNA) and Endo International (ENDP).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OSMT
• CIK: 1739426
• Web: www.osmotica.com
• Phone: (908) 809-1300
• Fax: N/A
• Employees: 302
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.59 million
• Net Margins: -138.76%
• Pretax Margin: -167.59%
• Return on Equity: -81.23%
• Return on Assets: -20.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.42

Sales & Book Value

• Annual Sales: $177.88 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.00
• Book Value: $1.50 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 62,585,000
• Free Float: 59,318,000
• Market Cap: $69.47 million
• Optionable: Not Optionable
• Beta: 2.34